Analysts in Q3 were more focused on medical-surgical challenges, a shift from Q2’s broader interest in oncology and specialty growth. McKesson delivered strong Q3 2025 results, driven by double ...
McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter ...
Barchart on MSN14d
Is McKesson Stock Outperforming the Dow?Valued at a market cap of $80.4 billion, McKesson Corporation (MCK) is a leading healthcare services and information ...
Connor Clark & Lunn Investment Management Ltd. grew its holdings in McKesson Co. (NYSE:MCK – Free Report) by 300.6% during ...
This growth resulted from increased third-party logistics and technology services, emphasizing McKesson's role in medication access and affordability. Conversely, its Medical-Surgical Solutions ...
McKesson has a 12-month low of $464.42 and ... Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic ...
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and McKesson fits this criterion perfectly. It provides pharmaceutical distribution, medical-surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results